To evaluate the efficacy and safety of AVP-@ , a drug-device combination of low-dose sumatriptan powder ( @mg loaded dose ) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder ( placebo device ) in the treatment of migraine headache .